4.5 Article

Ventricular features as reliable differentiators between bvFTD and other dementias

期刊

NEUROIMAGE-CLINICAL
卷 33, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2022.102947

关键词

Frontotemporal dementia; Dementia; Brain imaging; Lateral ventricles - Classification

资金

  1. Canadian Consortium on Neurodegeneration in Aging
  2. Alzheimer Society Research Program (ASRP) postdoctoral award
  3. Canadian Institutes of Health Research
  4. Alzheimer Society of Canada
  5. Sanofi
  6. Women's Brain Health Initiative
  7. Canadian Institutes of Health Research [MOP-111169]
  8. Fonds de Research SanteQuebec Pfizer Innovation fund
  9. NSERC CREATE grant [4140438 -2012]
  10. Famille Louise Andre Charron
  11. Fonds de Recherche du Quebec Sante (FRQS)
  12. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  13. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  14. National Institute on Aging
  15. National Institute of Biomedical Imaging and Bioengineering
  16. AbbVie
  17. Alzheimer's Association
  18. Alzheimer's Drug Discovery Foundation
  19. Araclon Biotech
  20. BioClinica, Inc.
  21. Biogen
  22. Bristol-Myers Squibb Company
  23. CereSpir, Inc.
  24. Cogstate
  25. Eisai Inc.
  26. Elan Pharmaceuticals, Inc.
  27. Eli Lilly and Company
  28. EuroImmun
  29. F. Hoffmann-La Roche Ltd
  30. Genentech, Inc.
  31. Fujirebio
  32. GE Healthcare
  33. IXICO Ltd.
  34. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  35. Johnson & Johnson Pharmaceutical Research & Development LLC.
  36. Lumosity
  37. Lundbeck
  38. Merck Co., Inc.
  39. Meso Scale Diagnostics, LLC.
  40. NeuroRx Research
  41. Neurotrack Technologies
  42. Novartis Pharmaceuticals Corporation
  43. Pfizer Inc.
  44. Piramal Imaging
  45. Servier
  46. Takeda Pharmaceutical Company
  47. Transition Therapeutics
  48. Frontotemporal Lobar Degeneration Neuroimaging Initiative (National Institutes of Health Grant) [R01 AG032306]

向作者/读者索取更多资源

This study used an automated tool to analyze lateral ventricles and found that ventricular features, particularly the antero-posterior ratio (APR), may be reliable and easy-to-implement markers for the diagnosis of behavioral variant frontotemporal dementia (bvFTD). Differentiating bvFTD from other dementia cohorts achieved a high accuracy using either other ventricular features or just the APR feature alone.
Introduction: Lateral ventricles are reliable and sensitive indicators of brain atrophy and disease progression in behavioral variant frontotemporal dementia (bvFTD). We aimed to investigate whether an automated tool using ventricular features could improve diagnostic accuracy in bvFTD across neurodegenerative diseases. Methods: Using 678 subjects 69 bvFTD, 38 semantic variant, 37 primary non-fluent aphasia, 218 amyloid + mild cognitive impairment, 74 amyloid + Alzheimer's Dementia and 242 normal controls- with a total of 2750 timepoints, lateral ventricles were segmented and differences in ventricular features were assessed between bvFTD, normal controls and other dementia cohorts. Results: Ventricular antero-posterior ratio (APR) was the only feature that was significantly different and increased faster in bvFTD compared to all other cohorts. We achieved a 10-fold cross-validation accuracy of 80% (77% sensitivity, 82% specificity) in differentiating bvFTD from all other cohorts with other ventricular features (i.e., total ventricular volume and left-right lateral ventricle ratios), and 76% accuracy using only the single APR feature. Discussion: Ventricular features, particularly the APR, might be reliable and easy-to-implement markers for bvFTD diagnosis. We have made our ventricle feature estimation and bvFTD diagnostic tool publicly available, allowing application of our model in other studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据